Johnson & Johnson (NYSE: JNJ) reported one-year data from Phase 3 clinical trials showing its psoriasis drug ICOTYDE maintained skin clearance rates through 52 weeks of treatment.

In the ICONIC-ADVANCE 1 and 2 studies, complete skin clearance rates increased from 41% to 49% and 33% to 48% respectively between weeks 24 and 52 among patients taking ICOTYDE. Patients who switched from placebo to the drug at week 16 achieved similar clearance rates by week 52.

The company presented the findings at the American Academy of Dermatology Annual Meeting. ICOTYDE is approved in the U.S. for treating moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg.

In a separate adolescent study called ICONIC-LEAD, nearly 60% of patients achieved completely clear skin at week 52, with 86% reaching PASI 90 response at one year. The safety profile remained consistent with earlier trial periods, with no new safety signals identified.

ICOTYDE is an oral peptide that blocks the IL-23 receptor and is taken once daily. The drug was jointly discovered with Protagonist Therapeutics, with Johnson & Johnson holding exclusive worldwide development and commercialization rights.

The company is also studying ICOTYDE for psoriatic arthritis, ulcerative colitis and Crohn's disease in ongoing clinical trials.